55 Retrospective analyses on toxicity in esophageal cancer patients [15] Vivekanandan S, Landau DB, Counsell N, Warren DR, Khwanda A, Rosen SD, et al. The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017;99:51–60. https://doi.org/10.1016/j.ijrobp.2017.04.026. [16] Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, et al. Clinical and Translational Radiation Oncology Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 2019;17:17–23. https://doi.org/10.1016/j. ctro.2019.04.016. [17] Rice TW, Blackstone EH, Rusch VW. Editorial: 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721–4. https://doi.org/10.1245/ s10434-010-1024-1. [18] Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011;79:10–8. https://doi.org/10.1016/j.ijrobp.2009.10.058. [19] Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyenberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Disagnosis (TRIPOD): Explanantion and Elaboration. Ann Intern Med 2015;162:W1–74. https://doi.org/10.7326/M140698. [20]Gergel TJ, Leichman L, Nava HR, Blumenson LE, Loewen GM, Gibbs JE, et al. Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis. Cancer J 2002;8:451–60. [21] Asakura H, Hashimoto T, Zenda S, Harada H, Hirakawa K, Mizumoto M, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol 2010;95:240–4. https://doi. org/10.1016/j.radonc.2010.02.006. [22]Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M, et al. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol 2015;88. https://doi.org/10.1259/ bjr.20140168. [23]Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707–14. https://doi.org/10.1016/j.ijrobp.2007.10.056. [24]“Port Meta-analysis Trialists group.” Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998;352:257–63. [25]Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensitymodulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:1078–85. https://doi.org/10.1016/j.ijrobp.2012.02.015. [26]Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol 2015;6:516–23. https:// doi.org/10.3978/j.issn.2078-6891.2015.040. [27]Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: An analysis of the surveillance, epidemiology, and end result database. PLoS One 2016;11. https://doi.org/10.1371/journal.pone.0158916. [28]Tucker SL, Liu A, Gomez D, Tang LL, Allen P, Yang J, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 2016. https://doi.org/10.1016/j.radonc.2016.04.025. [29]Lin J Bin, Hung LC, Cheng CY, Chien YA, Lee CH, Huang CC, et al. Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy. Radiat Oncol 2019;14:1–10. https://doi.org/10.1186/s13014-019-1283-3. [30]Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, et al. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 2019;141:33–40. https://doi.org/10.1016/j.radonc.2019.09.015. 4
RkJQdWJsaXNoZXIy MTk4NDMw